Pfizer has secured European Commission approval to carry out updates to the summary of product characteristics (SmPC) for its pneumococcal conjugate vaccine (PCV) Prevenar 13, regarding its use in certain high-risk populations. Now the ...
Tags: Pfizer, Label Update
Pfizer has obtained European approval for the expanded use of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), in adults between 18 to 49 years of age for the prevention of invasive pneumococcal disease. ...
Tags: Pneumococcal Vaccine, Medicine
Immunobiology (ImmBio), a UK-based biopharmaceutical company, has bagged £0.2m in funding from the UK government-backed Biomedical Catalyst (BBC) for the pre-clinical development of pneumococcal vaccine PnuBioVax. The pharma company ...
Vaccines aren't just for kids. There are nearly a dozen recommended vaccines besides flu shots for grownups age 19 and older to protect against preventable diseases, such as pneumococcal disease, whooping cough, and shingles. But most ...
Pfizer has obtained FDA approval for the expanded use of Prevnar 13, pneumococcal conjugate vaccine, in children and adults between six to 17 years of age who are new to the vaccine. The single dose Pneumococcal 13-valent conjugate ...
Tags: FDA, vaccine, conjugate vaccine
Pfizer has obtained the European Commission approval for the use of Prevenar 13 vaccine in older children and adolescents aged six to 17 years for the prevention of pneumococcal disease. Single dose of the pneumococcal conjugate vaccine ...
Tags: vaccine, Pfizer, pneumococcal disease, medicines